Satoreotide bought out from
IPSEN by VC Syndicate
About Us
Ariceum Therapeutics is a private company focused on developing novel targeted radiopharmaceuticals for the treatment of cancer
Our lead targeted systemic radiopharmaceutical product, 177Lu-satoreotide tetraxetan (Satoreotide), is an antagonist of the somatostatin type 2 receptor (SSTR2) which is overexpressed in many neuroendocrine tumours. We are developing satoreotide as a ‘theranostic’ pair for the combined diagnosis and targeted radionuclide treatment of neuroendocrine cancers, certain aggressive tumours, which currently have few treatment options and a poor prognosis.
Our second more advanced therapeutic product, ATT001 is a novel 123Iodine radiolabeled PARP inhibitor (rPARPi) which will soon enter a Phase 1 clinical study in recurrent glioblastoma patients, an indication of high unmet medical need. Ariceum intends to expand the development of ATT001 into other fast growing PARP expressing tumours.
Through our partnership with UCB Pharma, we will explore new targets to develop first-in-class radiopharmaceuticals to continue expanding our pipeline beyond the two lead assets.
Ariceum Therapeutics was launched in 2021, following the acquisition of all rights to our lead product from subsequent shareholder, Ipsen.
Headquartered in Berlin, Ariceum has operations in Germany, Switzerland and Australia, and is active across Europe, North America and Australia.
Milestones
October 2021
June 2022
April 2023
May 2023
June 2023
Vision
Create a better future for cancer patients
Mission
Innovate by caring about patients
Become the go-to-company for more specific and more effective radiopharmaceuticals
Unleashing the power of radiopharmaceuticals
Develop better targeted drugs to eradicate cancer more efficiently
with less side-effects
© Ariceum Therapeutics
